ICU Medical (ICUI) Stock Price
ICU Medical Price
Over the last 19 years ICU Medical grew revenue by 13.5% annually, reaching 2.23 B USD. Earnings per share have declined at 19.3% per year over the last 19 years. For ICU Medical, the net margin of 0.0% is down versus 7.8% a few years ago. The consensus 12-month price target for ICU Medical is 187.00 USD, about 17.5% above where the stock trades today. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus.
ICU Medical stock price
ICU Medical business model & stock analysis
Frequently asked questions about ICU Medical
ICU Medical Inc is a healthcare company that specializes in the development, manufacture, and sale of medical devices, consumables, and services. Its business model revolves around providing innovative and cost-effective solutions to improve patient care and safety. ICU Medical Inc focuses on critical care, oncology, and infusion therapy markets, offering products like infusion pumps, needle-free connectors, and custom infusion sets. By collaborating with healthcare professionals and maintaining a customer-centric approach, the company aims to enhance patient outcomes and streamline healthcare delivery. ICU Medical Inc's commitment to innovation, quality, and customer satisfaction drives its business strategy and growth in the healthcare industry.
ICU Medical Inc is primarily active in the healthcare industry.
The main competitors of ICU Medical Inc in the market include Becton, Dickinson and Company, Fresenius Kabi AG, and Baxter International Inc.
ICU Medical Inc. is a renowned company in the healthcare industry. Established in 1984, ICU Medical has a rich history of delivering innovative medical devices and solutions. The company provides a wide range of products, including infusion therapy, critical care, and oncology systems, designed to enhance patient safety and improve medical outcomes. ICU Medical has grown significantly over the years and has become a global leader in infusion therapy technology. With a commitment to quality and continuous innovation, ICU Medical continues to play a vital role in revolutionizing the healthcare sector and improving patient care worldwide.
ICU Medical Inc., a leading global provider of medical devices, has achieved several significant milestones over the years. One notable achievement is the acquisition of Hospira Infusion Systems from Pfizer in 2017. This strategic acquisition expanded ICU Medical's product portfolio and strengthened its position in the infusion therapy market. Additionally, ICU Medical Inc. received FDA clearance for its innovative Clave™ Needlefree Connector, which has revolutionized intravenous therapy by reducing the risk of infections. Furthermore, the company has consistently demonstrated strong financial performance, marked by revenue growth and profitability. With a commitment to innovation and quality, ICU Medical Inc. continues to make strides in improving patient care and addressing critical healthcare challenges.
ICU Medical Inc is primarily present in the United States, with its headquarters located in San Clemente, California. In addition to its strong presence in the domestic market, ICU Medical Inc operates in various other countries and regions across the globe. The company has offices and facilities in Europe, including Germany, France, and the United Kingdom, as well as in the Asia-Pacific region, with locations in Australia, China, and Japan. With a global reach, ICU Medical Inc is able to serve healthcare institutions and providers worldwide, offering innovative medical technologies and solutions.
ICU Medical Inc represents the values of innovation, quality, and patient safety. With a commitment to advancing healthcare, the company focuses on developing and delivering innovative medical devices and solutions. ICU Medical Inc's corporate philosophy emphasizes collaboration, integrity, and a patient-centric approach. By consistently meeting the highest standards of excellence, the company strives to improve patient outcomes and enhance the overall healthcare experience. With a strong emphasis on research and development, ICU Medical Inc is dedicated to providing healthcare professionals with cutting-edge technologies that support optimal patient care.
Analysts currently set an average price target of 186.40 USD for the ICU Medical stock (median: 187.00 USD), implying +17.2 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the ICU Medical stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect ICU Medical to generate revenue of 2.19 B USD and earnings per share of 8.63 USD.
Converted at the current exchange rate, the ICU Medical share trades at 142.00 EUR (159.11 USD).
The ICU Medical share (ICUI) is listed on 5 stock exchanges, including: NASDAQ (ICUI), SIX (Zürich) (IC7.SW), Frankfurt (IC7.F), München (IC7.MU), Düsseldorf (IC7.DU).
ICU Medical Inc is a globally operating company specializing in the development and manufacturing of innovative medical products. The company serves various sectors such as infusion therapy, oncology, and intensive care medicine. With its extensive portfolio of products, ICU Medical Inc aims to contribute to improving patient care worldwide.
The expected revenue of ICU Medical is 2.19 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of ICU Medical is 213.15 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of ICU Medical is currently 18.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ICU Medical stock.
The price-to-sales ratio (P/S) of ICU Medical is currently 1.80. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ICU Medical stock.
The Eulerpool Quality Score for ICU Medical is 2/10.
The ISIN of ICU Medical is US44930G1076. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ICU Medical is 894139. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ICU Medical is ICUI. The ticker symbol is used to trade ICU Medical shares on the stock exchange.
ICU Medical stock
ICU Medical Peer Group
ICU Medical Ticker
ICU Medical FIGI
All fundamentals and in-depth analysis of ICU Medical
Our stock analysis for ICU Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ICU Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.